Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹107 Cr
Revenue (TTM)
₹106 Cr
Net Profit (TTM)
₹14 Cr
ROE
14.5 %
ROCE
19.5 %
P/E Ratio
7.7
P/B Ratio
1
Industry P/E
47.96
EV/EBITDA
3.2
Div. Yield
0 %
Debt to Equity
0
Book Value
₹90.4
EPS
₹11.3
Face value
10
Shares outstanding
12,304,636
CFO
₹91.71 Cr
EBITDA
₹134.11 Cr
Net Profit
₹71.09 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Par Drugs
| -14.4 | -8.9 | -19.4 | -10.9 | -14.0 | 9.0 | -- |
|
BSE Healthcare
| -1.6 | -1.6 | -2.9 | 1.0 | 25.6 | 15.4 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Par Drugs
| -51.1 | -8.4 | 42.8 | -24.9 | 470.1 | 65.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Par Drugs
|
86.6 | 106.6 | 106.4 | 13.9 | 13.6 | 13.5 | 7.7 | 1.0 |
| 2,527.3 | 20,674.9 | 1,215.1 | 284.8 | 28.7 | 21.1 | 72 | 13.6 | |
| 694.2 | 13,647.4 | 7,266.8 | 627.5 | 11.9 | 12.6 | 21.7 | 2.5 | |
| 629.1 | 15,580.2 | 5,092.5 | 545.5 | 15.9 | 14.1 | 28.6 | 3.8 | |
| 859.7 | 13,775.4 | 7,918.4 | 429.9 | 10.7 | 7.2 | 31.8 | 2.1 | |
| 973.7 | 17,440.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.2 | 2.0 | |
| 1,334.1 | 15,557.0 | 1,419.3 | 20.1 | 8.4 | 0.5 | 773.9 | 2.7 | |
| 141.1 | 18,755.7 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 418.8 | 16,887.2 | 3,720.2 | 352.1 | 13.7 | 8.2 | 48 | 3.6 | |
| 1,197.2 | 19,469.8 | 3,151.0 | -10.0 | 8.4 | 2.5 | 885 | 4.2 |
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP,... dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, Alusil, PARSIL-HT, aluminium hydroxide magnesium carbonate co-dried gel, magnesium aluminium silicate hydrated (pharma), and magnesium aluminium silicate hydrated (agro). It also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India. Read more
Incorporated
1999
Chairman
Falgun Vallabhbhai Savani
Managing Director
Falgun Vallabhbhai Savani
Headquarters
Vadodara, Gujarat
Website
Looking for more details about Par Drugs And Chemicals Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Announcements
View Announcements
The share price of Par Drugs And Chemicals Ltd is ₹86.64 (NSE) as of 25-Mar-2026 IST. Par Drugs And Chemicals Ltd has given a return of -13.95% in the last 3 years.
The P/E ratio of Par Drugs And Chemicals Ltd is 7.67 times as on 25-Mar-2026, a 84 discount to its peers’ median range of 47.96 times.
The P/B ratio of Par Drugs And Chemicals Ltd is 0.96 times as on 25-Mar-2026, a 69 discount to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
7.82
|
1.06
|
|
2024
|
18.28
|
3.10
|
|
2023
|
15.20
|
2.42
|
|
2022
|
21.34
|
3.28
|
|
2021
|
3.28
|
1.46
|
The 52-week high and low of Par Drugs And Chemicals Ltd are Rs 122.43 and Rs 81.01 as of 26-Mar-2026.
Par Drugs And Chemicals Ltd has a market capitalisation of ₹ 107 Cr as on 25-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Par Drugs And Chemicals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.59
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.